Neuroimaging of Dopamine Transporter Density in the Striatum of Disordered Gamblers

Imagem de Miniatura
Arquivos
art_GUERRA_Neuroimaging_of_Dopamine_Transporter_Density_in_the_Striatum_2023.PDF (1.35 MB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
BATISTA, Ilza Rosa
KIM, Hyoun S.
SHIH, Ming Chi
BRESSAN, Rodrigo Affonseca
Citação
JOURNAL OF GAMBLING STUDIES, v.39, n.1, p.119-136, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The aim of the present research was to add to the growing literature on dopamine and gambling disorder (GD) by assessing whether GD is associated with dopamine transporter (DAT) density in the ventral striatum compared to healthy controls and whether DAT density was associated with key characteristics of GD (e.g., abstinence, craving). In a cross-sectional investigation using single-photon emission computed tomography with a technetium-(99)m-labeled tropane derivative as a radiotracer with SPECT imaging, fifteen participants with GD and 15 controls (non-gambling individuals, matched for age, gender, handedness, and smoking status) were measured. The GD group completed self-reported questionnaires regarding gambling. Striatal DAT density did not differ between the two groups. Conversely, striatal DAT density correlated significantly with various measures of recent gambling, but not with measures of chronic gambling. Multivariate analysis, adjusted for age and smoking status, showed that DAT density in the left striatum correlated positively with time spent gambling and gambling craving in the last month, whereas DAT density in the right striatum correlated negatively with abstinence self-efficacy. The results suggests that DAT density in the striatum is associated with recent gambling activity and gambling expectation.
Palavras-chave
Gambling disorder, Dopamine transporter, TRODAT-1-Tc-99m, SPECT
URI
https://observatorio.fm.usp.br/handle/OPI/53069
Referências
  1. Acton PD, 2000, EUR J NUCL MED, V27, P1714, DOI 10.1007/s002590000371
  2. American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/APPI.BOOKS.9780890425596
  3. Berridge KC, 2016, AM PSYCHOL, V71, P670, DOI 10.1037/amp0000059
  4. Berridge KC, 2009, CURR OPIN PHARMACOL, V9, P65, DOI 10.1016/j.coph.2008.12.014
  5. Brunswick DJ, 2003, AM J PSYCHIAT, V160, P1836, DOI 10.1176/appi.ajp.160.10.1836
  6. CHANG LT, 1978, IEEE T NUCL SCI, V25, P638, DOI 10.1109/TNS.1978.4329385
  7. Clark L, 2019, MOL PSYCHIATR, V24, P674, DOI 10.1038/s41380-018-0230-2
  8. Clark L, 2012, NEUROIMAGE, V63, P40, DOI 10.1016/j.neuroimage.2012.06.067
  9. Comings DE, 2001, CLIN GENET, V60, P107, DOI 10.1034/j.1399-0004.2001.600204.x
  10. Erro R, 2012, PARKINSONISM RELAT D, V18, P1034, DOI 10.1016/j.parkreldis.2012.05.022
  11. Fiorillo CD, 2003, SCIENCE, V299, P1898, DOI 10.1126/science.1077349
  12. Freitas S., 2001, REV BRAS PSIQUIATR, V23, P215, DOI 10.1590/S1516-44462001000400008
  13. Galetti AM, 2017, REV BRAS PSIQUIATR, V39, P36, DOI 10.1590/1516-4446-2016-1911
  14. Gorenstein C, 1996, BRAZ J MED BIOL RES, V29, P453
  15. Hodgins D. C., 2004, INT GAMBL STUD, V4, P99, DOI 10.1080/14459790412331296947
  16. Johanson CE, 2006, PSYCHOPHARMACOLOGY, V185, P327, DOI 10.1007/s00213-006-0330-6
  17. Joutsa J, 2012, NEUROIMAGE, V60, P1992, DOI 10.1016/j.neuroimage.2012.02.006
  18. Karila L, 2016, NEUROPSYCHOPHARMACOL, V41, P2294, DOI 10.1038/npp.2016.28
  19. Kim HS, 2018, EUR EAT DISORD REV, V26, P508, DOI 10.1002/erv.2606
  20. Laine TPJ, 1999, MOL PSYCHIATR, V4, P189, DOI 10.1038/sj.mp.4000514
  21. Linnet J, 2010, ACTA PSYCHIAT SCAND, V122, P326, DOI 10.1111/j.1600-0447.2010.01591.x
  22. Linnet J, 2011, ADDICTION, V106, P383, DOI 10.1111/j.1360-0443.2010.03126.x
  23. Lorains FK, 2011, ADDICTION, V106, P490, DOI 10.1111/j.1360-0443.2010.03300.x
  24. Majuri J, 2017, NEUROPSYCHOPHARMACOL, V42, P1169, DOI 10.1038/npp.2016.265
  25. McCann UD, 1998, J NEUROSCI, V18, P8417
  26. Merkouris SS, 2016, CURR ADDICT REP, V3, P254, DOI 10.1007/S40429-016-0106-Y
  27. Pettorruso M, 2019, ADDICT BIOL, V24, P1077, DOI 10.1111/adb.12677
  28. Potenza MN, 2018, BIOL PSYCHIAT, V83, P984, DOI 10.1016/j.biopsych.2018.04.011
  29. Potenza MN, 2008, PHILOS T R SOC B, V363, P3181, DOI 10.1098/rstb.2008.0100
  30. Rigoli F, 2016, NEUROPSYCHOPHARMACOL, V41, P2658, DOI 10.1038/npp.2016.68
  31. Sekine Y, 2001, AM J PSYCHIAT, V158, P1206, DOI 10.1176/appi.ajp.158.8.1206
  32. Silveira Dartiu X., 2000, Revista Brasileira de Psiquiatria, V22, P4, DOI 10.1590/S1516-44462000000100003
  33. Tang KTY, 2020, PSYCHIAT RES, V284, DOI 10.1016/j.psychres.2020.112763
  34. van Holst RJ, 2018, BIOL PSYCHIAT, V83, P1036, DOI 10.1016/j.biopsych.2017.06.010
  35. Verplaetse TL, 2018, CURR OPIN BEHAV SCI, V23, P196, DOI 10.1016/j.cobeha.2018.04.004
  36. Volkow ND, 2001, AM J PSYCHIAT, V158, P377, DOI 10.1176/appi.ajp.158.3.377
  37. Volkow ND, 2003, J NEUROSCI, V23, P11461
  38. VOLKOW ND, 1993, SYNAPSE, V14, P169, DOI 10.1002/syn.890140210
  39. Yang YK, 2008, PROG NEURO-PSYCHOPH, V32, P274, DOI 10.1016/j.pnpbp.2007.08.018

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/23